Aurora Cannabis (NYSE, TSX:ACB) 2019 and 2020 outlook.

Aurora Cannabis (NYSE, TSX:ACB)


Aurora Cannabis (NYSE, TSX:ACB) is a Canadian producer and distributor of medical cannabis. In terms of market capitalisation, it is the world’s second largest cannabis company after Canopy Growth. With an ever-increasing revenue, reduced costs, and positive projected financials, Aurora’s future is that of rapid growth. ACB also ranks #1 on our Cannabis poll.


Aurora Cannabis is a medical cannabis producer and distributor. It is a Canadian licensed company with authorised production and sales operations in more than 20 countries. The company is listed on the New York Stock Exchange (NYSE) and the Toronto Stock Exchange (TSX) under the ticker symbol ACB.

Aurora was initially founded in 2006 in Mountain View County, Alberta, where it established its first production facility. Later, it became the first federal government licensed cannabis-growing company of the province in 2014. In November same year, it received the license from Health Canada to grow and market medical cannabis. The company has its headquarters in Edmonton, Alberta.

It uses a business model which emphasizes vertical integration and horizontal diversification. Consequently, it continuously strives to reduce reliance on suppliers, lower costs and improve its economies of scale. Also, its operations are significant ranging from facility design and engineering, cannabis genetic research, cannabis, hemp, and derivatives production.

Therefore, it has opportunities to benefit from growth in every part of the industry’s value chain. Leveraging that, it has been able to develop an unparalleled international reach advantage. Currently, Aurora has an estimated peak production capacity of up to 700,000 kilos.

Industry Overview

Classified as a health care company, Aurora is specifically in the cannabis industry. Experts do not always agree on choices of investment. However, it seems they all agree on the immense potential of the medical cannabis industry.

The legal cannabis industry is the fastest-growing industry in the United States. The industry has two major segments: the recreational/adult use and medical markets. Analysts expect recreational use to account for approximately 67% of the growth while medical use will contribute the rest. Recreational cannabis is already legal in nine American states while medical marijuana is legal in 33.

Interestingly, the largest cannabis companies in the world are Canadian. The most contributory factor to this is the country’s cannabis-friendly stance. Ontario-based Canopy Growth, with its market capitalisation of approximately $23 billion, is clearly the largest in the industry. Tilray, Aurora, and Scotts Miracle-Gro follow it.

The Canadian companies have also been infiltrating the American cannabis industry by making substantial investments in US-based marijuana firms. They can more easily expand than their American counterparts because they face lesser regulatory hurdles and are more flush with cash. With the projected compound annual growth rate of 26.6%, perhaps, there is no other industry that matches the growth potential of the legal marijuana industry.

Aurora Cannabis: Benefitting From Massive Industry Growth

Presently, cannabis stocks are wildly popular, especially among millennial investors. After delivering $6.9 billion in global sales in 2016, the industry was able to grow this by approximately 38% in 2017. For 2018, the industry posted an estimated $12.2 billion in revenue, a figure that has been projected to rise by 38% to $16.6 billion for 2019.

In short, generally, the cannabis industry is of a good prospect. Revenue is expected to be on a consistent increase. Consequently, its companies will grow and their stocks will generate significant value for their investors. However, a cannabis company that wants to thrive must focus on key business fundamentals such as financing, product diversity and differentiation, and strategic partnerships, among others. Aurora Cannabis is doing just that.

Strategic Partnerships: The Primary Driver of Aurora’s Growth

Aurora actively seeks to expand. Its expansion strategy based on vertical integration and horizontal diversification is a sound one. Anandia Laboratories, the global industry leader in cannabis testing and research, is its wholly-owned subsidiary. Also, Agropro UAB, Europe’s largest producer and supplier of certified hemp, is another. Moreover, Aurora announced its acquisition of Farmacias Magistrales, a Mexico-based medical cannabis firm, in December 2018.

Aurora, through its policy of strategic acquisition, is also the owner of Pedanios GMBH, now Aurora Deutschland. Pedanios GMBH is Germany’s largest supplier of medical cannabis to pharmacies, with over 750 pharmacies supplied. CanvasRx, BC Northern Lights, CanniMed Therapeautics, and Borela UAB are some of the other companies Aurora has long acquired.

The latest of Aurora’s strategic partnerships, its “exclusive, multi-year, multi-millionaire, global partnership” with the Ultimate Fighting Championship (UFC) to advance cannabidiol research, came through on May 21, 2019.

Diversified Product Offering And Consumer Recognition

Aurora arguably has the most diversified product offerings in the industry. Little wonder that the brand-consumer recognition is strong, having fast outpaced its peers. Currently, the company markets its adult consumer products via the four main and active brands: Aurora, Altavie, San Rafael’71, and Woodstock.

Of course, these two factors are vital drivers of its growth, and will continue to boost its revenue in the coming years. Add to this its rapid product diversification through acquisitions, research and development, and strategic partnerships. As a result, you will conclude that Aurora’s prospect for the future is that of rapid growth.

Healthy Financials Confirm Positive Outlook

By the end of Q1 2019, Aurora Cannabis (ACB) has gained approximately 83% while the S&P 500 appreciated only by 15.5%. Over the past two years, Aurora Cannabis has appreciated by 326.4% compared to the 24.3% gained by the S&P 500 during the same period. Despite sustaining a loss in 2017, the company closed 2018 in the green.

With a market capitalisation of approximately $8 billion, Aurora (ACB) currently hovers around $8. For 2019, it has posted a YTD appreciation of approximately 70%. With a projected P/E ratio of 85.8×, its upward potential is still high, leaving room for opportunities to mount the ride.


Yes, the cannabis industry has become widely favoured. However, you should take note that regulatory restrictions in different countries can reasonably impede its growth. We believe the optimistic views of most analysts on it will pan out nevertheless.… Read More

Which Cannabis stocks are the best to buy? Come vote for the one you like.

Which Cannabis stocks are the best to buy?

Marijuana stocks have been one of the most talked about sectors since Canada made recreational use legal last year.  Many analyst are predicting that the marijuana industry could grow to 50-130 billion in revenue by 2030. These analyst believe it could become a bigger market than the Alcohol beverages market which currently takes up 16.5% of the US beverage market. I believe some of these estimates are very optimistic and some may be unrealistic, even though the Global Alcohol beverage market has slower growth and a CAGR of just over 3% compared to the marijuana market which is around 25% CAGR. Regardless of how bullish you are with the estimates almost everyone can agree that the Cannabis market still is looking at huge growth over the next ten years.

Short Summary of the top Cannabis stocks

I am not here to tell you which stock you should buy or which company you should invest in. What I will do is provide short summaries based on recent events with the company so you can make your own decisions.

CGC – Canopy Growth – TSX: WEED

Canopy Growth as of 05/09/2019 is currently at 46.90 a share and has a current market cap of 16.26 Billion. They have 344.14 million shares outstanding.  The average volume over the last 10 days is 6.6 million. They have an EPS of -2.01 and a revenue per employee of $115,040. The company CEO is Bruce Linton. Over 144,000 Robinhood users currently have shares of the stock.

Canopy made a huge splash last year when Constellation the company that makes the beer Corona bought 38% of the company. At the time they spent billions to buy shares of Canopy at an average premium of over 51% of the market value at the time. This acquisition brought a lot of attention to the entire Cannabis Sector.

In recent news Canopy has signed a condition agreement with Acreage Holdings a US based marijuana company. This agreement will allow CGC to make a quick transition to the American market if/when Cannabis is legalized on a federal level. CGC also has recently acquired C3 the German based Cannabinoid Compound company. This acquisition allows them to have access to the medical marijuana market with the product Dronabinol. Canopy has been very active in establishing new brands and making new supply agreements.

HEXO – Hexo Corp. TSX: Hexo

Hexo is currently at $7.37 a share and has a current market cap of 1.58 billion.  They have 210.61 million Outstanding shares. The average volume over the last 10 days has been 4.12 million shares traded. It’s current EPS is at -0.11.  The CEO is Sebastien St. Louis. Currently over 118,000 Robinhood user own shares of it.

Hexo has received an agreement to supply a large amount of marijuana in Quebec which is the second most populated providence in Quebec. Hexo market share in Quebec is currently just under 40% which is a significant amount of market share. Last year Hexo announced a joint agreement with Molson Coors Brewing company to develop  Cannabis-infused beverages. Hexo acquired Newstrike Brands which gives them almost 500,000 square feet of production capacity. Hexo specializing in CBD and a lot of investors are drawn to its lower market cap.

TLRY- Tilray Inc.

TLRY is currently at 46.40 a share with a current market cap of 4.46 Billion. They currently have 80.13 million shares outstanding.  They have an EPS of -.073 and have revenue of $62,690 per employee. Brendan Kennedy is the CEO. just over 35,000 users of Robinhood own shares of it.

TLRY just announced this week it plans to spend 32.6 million to add an addition 200,000 sq. ft to three facilities. The company now has almost 1.4 million Sq Ft for its product and manufacturing world wide. TLRY is one of the few cannabis stocks that is down for the year largely due to insider selling. Privateer Holdings which owns the majority of TLRY decided not to sell their shares when the lockout ended earlier this year. At the time the stock was at nearly $100 a share. TLRY has yet to get a big deal like CRON and CGC. Given most of the float being locked up it is very possible there could be a price increase before Privateer Holdings sells their shares.

CRON – Cronos Group INC.

CRON has a current share price of 14.10 a share.  It’s market cap is 2.75 Billion and has an EPS of -0.08. It’s average Revenue per Employee is at $19,100. The CEO is Michael Gorenstein. It has roughly 187,000 users of Robinhood that own shares in it.

CRON received 1.8 billion from Altria Group. that equity investment at the end of last year brought a lot of attention to Cronos and the stock price went up significantly.  Altria has a lot of resources at their disposal which could mean they could help a lot with the growth and expansion. CRON reported a 120% increase in year over year revenue the first Quarter. Cronos stock price is coming back down to earth and may be a good one to watch soon.

ACB – Aurora Cannabis Inc.

ACB is currently at $8.38 a share. It has a market cap of 8.7 billion and currently has 1.01 billion shares outstanding. Its EPS is -0.02 and its revenue per employee is $94,400. Nearly 440,000 Robinhood users own shares of ACB.

ACB focuses on both the recreational and the medical marijuana market. They just hired billionaire activist investor Nelson Peltz as a strategic advisor. They currently in twenty four different countries. ACB has the production capacity that allows it to outproduce all other marijuana companies.


Now it is your turn to vote on which marijuana stock will do the best over the next five years.


















 … Read More

POTN-PotNetwork Holding


POTN is the ticker symbol for the company PotNetwork Holding and it is dedicated to R&D and distribution of the cannabis products along with some other verticals. The company has been working since 2004 and is selling its products all over the US. The international network of PotNetwork Holding is increasing rapidly and the company’s futuristic approach is quite lucrative.

The CEO of the company is Dr. Richard Goulding and the President is Kevin L Hagen. It is up-listed on the OTCQB and has a good marketing visibility among the investors. The company’s milestone towards the achievement of long-term strategies is always progressive in its own ways. PotNetwork Holdings focuses on the rapid growth of verticals within the global cannabis industry. According to the researchers, there is a projected growth of $31.4 billion of this industry by 2021. The United States is the major player in this largest growing market of cannabis and commands over 90% of the worldwide sale.

POTN subsidiaries are as follows:

  • Diamond CBD
  • PotNetwork
  • Meds Biotech
  • First Capital Venture
  • MediPets
  • Grinders Distribution

The company has 15 well-known brands in CBD market and these are retailed through thousands of stores across the US. There are edible gummies, CBD oils, vape addictives, vape pens, pet merchandise and many more products offered by the company. The range of products is growing and the subsidiaries are very promising in their own way.

The 52-week range of POTN is $0.001 – 0.957. There was stock appreciation noted in the previous year with a drastic increase in network and sales. The further plans of the company aim at initiating revenues for becoming a fully-reporting company for enhancing the present status. The past year achievements are giving a boost to the investors to choose this marijuana stock. Sales have gone high in the previous year and the present scenario also reveals positive responsiveness. There are many new products offered by the company and many are in the queue. There are many unique aspects of the company giving a chance for growth of stock prices.

PotNetwork Holding has the entrusted team of advisors, managers, health experts and business professionals to lead the company to the top. The company is located in the State of Colorado and supplies its products all over the US. The average trading value of the stocks is 8,390,661 and it will increase in the next quarters. The recent announcement of company’s Q1 values for 2018 have been recorded as $6.3 million which is about thrice to the value of stock increase over the same period in 2017. The major growth is driven by the subsidiary Diamond CBD having successful distribution and networking of the products.

With the improvement in sales figures, the stockholders have become very optimistic about POTN and its transparency has increased among the investors for a better visibility in the market. The company also announced its objectives for aligning its corporate identity with core business objecting to become a leader in the CBD industry.… Read More

PHGRF Pres Release


Premier Health Group Inc. Announces binding LOI

VANCOUVER, British Columbia, December 17, 2018 /PRNewswire/ —

– Cloud Practice offers cloud-based electronic medical records software applications for physicians throughout Canada

– As per the latest reported financials, Cloud Practice is EBITDA[1] positive, resulting in immediate cash flow generation and earnings accretion for Premier Health

– Products include: Juno EMR, a cloud-based EMR solution; ClinicAid, a medical billing software; and MyHealthAccess, an online patient portal

– Juno EMR system is currently used by 287 clinics, over 3,000 licensed practitioners, 1,500 staff and 2,870,000 registered patients

– ClinicAid processes upwards of $30,000,000 in payments to over 3000 health providers on a monthly basis

– Cloud Practices founders, including CEO Jordan Visco, and entire support teamconsisting of several software developers and sales staff, to join Premier

Premier Health Group Inc. (PHGI.CN), (PHGI.CN), (PHGRF), (Frankfurt: 6PH), (Frankfurt: 6PH.F) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to announce that as a part of its technology platform, it has signed a binding LOI to acquire all of the outstanding securities of Cloud Practice Inc. (“Cloud Practice”).

Dr. Essam Hamza, CEO of Premier Health, said: “We are ecstatic at the opportunity to build on our patient centric technology platform through the integration of Cloud Practice’s suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare. We believe that this partnership will help facilitate our vision of integrating telemedicine, online booking and other premium services with our electronic medical record (EMR) system.”

Dr. Essam continued: “Cloud Practice already has a tremendous standalone and growing business serving thousands of clinicians and millions of patients. The collective ecosystem of over 3,000,000 patients creates an opportunity to become a key player in the telehealth space in Canada.”

Jordan Visco, CEO of Cloud Practice, stated: “We are very excited to be joining a forward-thinking group such as Premier Health. The synergies between our two teams will help enable us to better streamline processes, making healthcare more efficient for all. We are also excited to implement some upcoming new, leading edge applications to make our software the best in the industry.”

Terms of the Acquisition

In consideration for the purchase of all of the outstanding Cloud Practice securities, Premier will pay to the Cloud Practice shareholders total consideration of up to $5 million as follows: (i) $500,000 paid in cash on signing of the binding LOI as a refundable deposit, (ii) $500,000 in cash payable on closing, (iii) $500,000 in cash payable 90 days after closing, (iv) $500,000 in cash payable within six months of the LOI subject to the satisfaction of certain milestones related to the integration of the Juno EMR, and (v) an aggregate of $3 million payable in commons shares of Premier at a price to be determined in the context of the market.

The acquisition is subject to customary closing conditions, including the execution of a definitive acquisition agreement and receipt of Canadian Securities Exchange approval. Closing is expected to occur at or about the end of December.

Dr. Essam Hamza, MD
Chief Executive Officer

About Premier Health

Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. We are developing innovative health care approaches that combine human skill-based expertise with emerging technologies, with the goal of setting the gold standard for services in locations of interest worldwide. Premier Health’s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally. The HealthVue team has a strong track record of successfully creating value in healthcare and technology enterprises. The Management team has deep clinical, financial and operational expertise and a passion for improving healthcare for all patients.

About Cloud Practice

Cloud Practice is a cloud-based software solutions company focused on streamlining medical practice throughout Canada. They offer three products including Juno EMR, ClinicAid and MyHealthAccess. Juno EMR, a modified branch of an open-source electronic medical records (EMR) software which was originally released by McMaster University, is hosted in the cloud and can be accessed anywhere, anytime. ClinicAid is Canada’s easiest medical billing software. MyHealthAccess is an online patient portal which puts patients back in control of their health care through connecting with their clinics and booking appointments online.

Cautionary Statements 

This news release contains forward-looking statements that are based on Premier Health’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans, completion of its acquisition of Cloud Practice, and the timing thereof, the expected benefits to the Company following the integration of Cloud Practice’s software and the expected implementation of new applications, including the timing thereof, the expect growth to Cloud Practice’s business and the expected synergies resulting from the Company’s acquisition of Cloud Practice. Although Premier Health believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Premier Health undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

The Canadian Securities Exchange does

Read More

Marijuana Stocks To Watch

          Marijuana Stocks To Watch

There are three major markets where the marijuana stocks get traded, be it medicinal marijuana stock or recreational marijuana stock. These major markets see to the buying and selling, the investments and risk taking, the taxes, revenues, income and expenditure of marijuana. Namely: NASDAQ, NYSE and OTC (Over The Counter) trading.


Our Top 3 marijuana stocks to watch December and January

  1. PHGRF- Premier Health Group INC.
  2. PLPL- Plantai Biotechnology Inc.
  3.  RBII- Rising Biosciences, Inc.




     NASDAQ stands for the National Association of Securities Dealers Automated Quotations, it is an electronic stock market where tradings of securities are carried out. In the aspect of marijuana stocks, NASDAQ is an electronic trading ground for both medical and recreational marijuana.

Marijuana Stocks on the NASDAQ

     While the U.S government still forbids marijuana technically, but due to the legalization and regulation of marijuana around the States and Canada, the illegal sales are reducing and legal sales are increasing. Cultivation facilities are sprouting up, retail outlets are on the move and the stocks are in supply. Due to this, marijuana products have found their way into various products like mouth-wash (Sativex for example), gels, lotions, drugs (Epidiolex). Even with all this legalization propaganda loop-holes have been found and is being used. The major loop-hole being this; Canada has legalized the sale and us of cannabis, thus Canada can sell cannabis on American Soil due to the fact of a clause which states that sales of marijuana can take effect if it is legal in the state where it is produced.

  • Cronos group became the first company to trade on the NASDAQ after trading for years in Canada and was also the first pure-play marijuana stock trader.
  • Tilray Incorporated became the second major player of marijuana stock on NASDAQ few months later, becoming the first NASDAQ to offer an Initial Public Offering (IPO).
  • Cronos group has also partnered with MedMen which is a large cultivator, grower and retailer of cannabis in California, to increase their production rate and supply chain.

All these major developments has allowed marijuana to penetrate into the U.S exchange without breaching any rules and is giving their rivals, the recreational marijuana stock a run for the market.


The NYSE stands for New York Stock Exchange, this is the stock exchange based in New York City and controls most parts of the trading in the United States.

  • As of September, 2018, Canopy Growth became the only pure-play marijuana stocks trader on the New York Stock Exchange. Worth more than a billion dollars due a multi-billion dollar investment from Constellation Brands.
  • Aurora Cannabis a Canadian based multi-billion dollar marijuana dealer, having partnership deals with major multi-billion companies and is also the biggest production output of marijuana with over 700,000 kilograms annually.
  • Curleaf Holdings: Curaleaf holdings broke out in August, 2018, becoming the largest Initial Public Offering (IPO) marijuana stock on the NYSE boasting of its own dispensaries, cultivation facilities, supply network and processing sites.

Over The Counter

Over the counter trading deals with the trading of marijuana stocks in retail shops.

  • Green Thumb Industry operates OTC with a net worth of $1.7 billion, with over 69 retail stores in 8 different market after being given the licenses to operate.
  • Acreage Holdings operates OTC also with a net of $1.5 billion and has its own retail offices and implementation of cultivation facilities
  •   Learn the various markets that the stocks operate in and invest in them.


Disclaimer: has been compensated 20 thousand for the market awareness of PHGRF for the dates Nov. 1st through Dec. 31st 2018 Our opinion should be considered bias. The other of this post currently owns shares of both PHGRF and RBII that they plan to sell as a swing trade.… Read More

GTBP-Swing Trade

Take a look at this potential GTBP Swing Trade.

GTBP has been bouncing from the $1.90 range to the $2.30 range several times. This has been a swing trader’s wet dream!

Take a look at this chart

In the green, I circled the different buying points and selling points. In less than 1 month there have been 5 different times to flip this stock for 20% or more!  It is looking like the 6th time is setting up right now!



  • Cancer biotech stocks have a history of getting investors excited!

  • Several similar stocks have gone up thousands of percent!

  • If you can flip a stock like this and keep adding to your position after gaining 20% you can start making some serious money!

Disclaimer: Market News LLC, a Wyoming Corporation that has been compensated $20,000.00 by MAPH Enterprises LLC ( for a period beginning August 13, 2018 and ending September 13, 2018 to publicly disseminate information about (GTBP). We own zero shares, but we may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. (Full Disclaimer)… Read More


Icnaf– Integrated Cannabis Company



Our alert is ICNAF!



This is a Canadian Marijuana Company that has been flying under the radar but not for long!


The Company just released a game-changing product called X-SPRAYS 


The Company’s X-SPRAYS™ product line consists of eight market ready orally ingested spray products that are highly effective for overall health and well-being as well as general lifestyle.  Four products are available infused with hemp-based cannabidiol (CBD) and four products are formulated without a cannabidiol (CBD) infusion.  The state of the art formulations are free from artificial flavours, artificial colours, sugar, starch, wheat, soy, gluten, eggs, salt and dairy.  The sprays contain natural fruit and/or herbal flavours and are suitable for vegetarians and vegans.  The products are highly bioavailable such that the active ingredients in the sprays are already fully dissolved, so the vitamins and minerals do not need to be further broken down once swallowed, but are immediately available for use by the body. 

The X-SPRAYS™ product line is packaged in precise, metered dose and convenient spray tubes including a child-resistant version, both of which easily fit into a purse or pocket and are ideal for travel.  The container protects the liquid from light and air, ensuring the quality and shelf life of the ingredients.

The full product offering is listed below in Table 1.0.

Product NameProduct Description / Use
CBDStress relief, pain management
Sleep with CBDSleep aid, non habit forming
FocusMental clarity
ReliefGeneral relief
SleepSleep aid, non habit forming
EnergyEnergy boost
LibidoAphrodisiac, enhance sexual vitality

X-SPRAYS Test Marketing
Online sales of the X-SPRAYS™ were initiated in late 2017 and have continued up to the present.  These sales have been encouraging, considering the previously limited marketing budget, and the Company has seen numerous repeat customer orders which demonstrates product uptake and consumer affinity for the X-SPRAYS™.

In addition to Internet sales, the Company has test marketed selected products in two Medical Marijuana dispensaries in Colorado.  These sales began in February 2018 and continue.  Proceeds from these sales have been reinvested in Colorado marketing initiatives. The Company has learned, however, that marketing combined with in-store promotions can generate minimum sales in excess of 1 product per day in the retail environment. While this number is insignificant from a revenue perspective on a small scale retail distribution, it becomes significant when considering retail distribution outlets in the hundreds of locations. A single product selling only one unit per day in 100 stores could generate wholesale revenue in excess of tens of thousands of dollars per day.  The Company has four products that are CBD infused, four non-CBD infused and a soon to be launched line of THC products that will have multiple SKU’s.  With market testing complete, X-SPRAYS™ plans to roll out additional brick and mortar distribution throughout dispensaries, vape stores, gas stations, and convenience stores across the country.

Additionally, the Company intends to launch an aggressive online marketing campaign to drive sales through the utilization of traditional on-line channels and via established product influencers.

Acquisition Opportunities
“We are currently in the late stages of reviewing a short list of potential acquisition opportunities that would broaden our product offering from the existing X-SPRAYS™ line to potentially licensed Cannabis formulations in several US States,” said Mr. John Knapp, CEO of Integrated Cannabis Company.  The Company will provide additional updates as required.

About Integrated Cannabis Company
Integrated Cannabis Company, Inc. is comprised of dedicated scientists and product engineers who are passionate about health and creating health and lifestyle products utilizing advanced delivery systems and formulations. For more information, please visit the company’s website at:


“John Knapp”
Chief Executive Officer

For further information, please contact: 
Eugene Beukman

The CSE does not accept responsibility for the adequacy or accuracy of this release. 

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Market News LLC, a Wyoming Corporation that has been compensated $10,000.00 by MAPH Enterprises LLC ( for a period beginning September 10, 2018 and ending October 10, 2018 to publicly disseminate information about (ICNAF / ICAN). We own zero shares, but we may buy or sell additional shares of (ICNAF / ICAN) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. (Full Disclaimer)… Read More

If you are looking for just a one day Pump PHGRF is not for you.


 PHGRF-Premier Health group as our top stock of November!

This is a stock that is newly listed on the US markets!


We have put together a due diligence page here.


Here is why we are so excited about the telemedicine industry…..


According to Grandview research group, the Global telemedicine industry is expected to be around 113.1 billion in 2025. It is estimated to have a CAGR (Compound Annual Growth Rate) of 18.3% which is huge!



We were shocked to see this huge growth potential. So we wanted to look into other publicly traded companies that were into the Telehealth sector. The company that we found that has a similar share structure to PHGRF was a company called Teladoc which goes under the ticker symbol TDOC.  Below we have posted a chart of what the stock price of TDOC has done the last 2 1/2 years they have been a publicly traded company.



As you can see by the chart above TDOC went from being under $10 a share to now almost $70 a share in just the last 2 1/2 years. What excites us the most is TDOC has nearly the same exact share structure that PHGRF has. TDOC has 69.54 million Outstanding shares and PHGRF has only 61.16 million. Now obviously PHGRF is still an early stage company and TDOC is more well-established but we think it is a great comparison to what makes this industry and sector so exciting!


“If you want to become wealthy you need to think like those who are wealthy”

 Billionaire and founder of Virgin Group Richard Branson is so confident in Telemedicine being the next big thing, that he invested millions of his own money into the sector!



Is PHGRF right for you? That is up to you to decide but we definitely recommend checking out our page dedicated to PHGRF here.

Disclaimer: DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
Market News LLC’s business model is to receive financial compensation to promote public companies.  Market News LLC, a Wyoming Corporation that has been compensated $10,000.00 by Midam Ventures LLC for a period beginning October 26, 2018 and ending December 1, 2018 to publicly disseminate information about ( PHGRF) We own zero shares of PHGRF, but we may buy or sell additional shares of (PHGRF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. .  Our opinion on the stocks should be considered biased. Market News, LLC and/or its affiliates may hold, buy, and sell securities that are discussed on We reserve the right to buy or sell the shares of all the companies mentioned in any materials we produce at any time. trades are made with a company portfolio, the funds are not directly from Market News, LLC. Full disclaimer can be found at More

GW Pharmaceuticals is a Hot Stock to Own with Several Bullish products

GW Pharmaceuticals is a Hot Stock to Own with Several Bullish products

GW Pharmaceuticals Plc engages in the business of discovering, developing and commercializing novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company has market capitalization of $1.81B with an average of 208,179.

Its outstanding shares are standing around 21,765,014 while authorized share holders equity of 245 million.

Its average share volume is around 208,179 shares with a one year target price of $149 a share.

GW Pharmaceuticals has been a difficult stock to own over the past couple of years. The company ran up to highs of $125 a share on the back of the biotech bullrun, but essentially collapsed (again, on the back of action in the wider biotech market) to March 2016 lows of a little over $38 a share.

On the release of data from one of its three trials, however, an end-March rally saw it gain more than 100%, and it now trades for just over $81 a share.

The company just reported its latest earnings, and has sold off a bit as a result. We see this selloff as an opportunity to get in on a pullback, ahead of what is going to be a catalyst filled 24 months.

The company has cash on hand of $254 million, so liquidity strength shouldn’t be too much of a problem near term.

With such little markets to go at, incomes are not going to be tremendous from either sign, but rather they ought to effectively surpass the organizations present deals and would put the organization on the way to income generation.

That is not so much what’s critical, in any case. The huge thing about grabbing endorsements in these signs is the potential for a development on the affirmed focuses into the more extensive epilepsy space.

There are more than 10 million children in the US that experience the ill effects of epilepsy and that – if the FDA endorses Epidiolex – could rapidly turn into an objective business sector for GW in light of a supplemental NDA.

Read More



Perhaps no other name has personified the pot stock boom and bust more so than Hemp Inc (OTCMKTS:HEMP). The company’s share price currently trading around 0.02 a share and its 52 week range is $0.00 – $0.12 per share. Its outstanding shares are around 754,027,180, while authorized shares are at 5,500,000,000.

Hemp’s administration expects more beneficial business open doors in coming period. The purpose for this developing good faith is news of another state joining the gathering of 29 expresses that have legitimated industrial hemp.

Tom Wolf, the Governor of Pennsylvania, marked a bill that would permit the Pennsylvania Agriculture Department and in addition establishments of advanced education develop hemp for exploration use, specifically or through approved temporary workers.

Hemp’s auxiliary unit, IHM, is in the last period of conclusion. David Schmitt, the COO of IHM, said that modern hemp is recovering its reasonable position in the U.S. as demand for this normal fiber keeps on surging because of the economic advantage. Pennsylvania brags a rich history of hemp cultivating since 1700s. Truth be told, it had one district which was even named “Hempfield.” The awareness is developing as more states are prepared to attach to existing American society.

The tragic part is that Hemp was really gaining some ground. A month ago and following quite a while of holding up, Hemp at last created its first naturally benevolent item to-market from the organization’s new decortication plant in Spring Hope, North Carolina.

This was an entirely major ordeal for HEMP and its speculators as the organization has fundamentally wagered the farm on this plant and the condition of North Carolina. Analyst believes that the organization was making a rebound and things were at long last beginning to meet up.

Read More

Marijuana Industry is Risky, Traders are looking to Profit from Investments

Marijuana Industry is Risky, Traders are looking to Profit from Investments

Marijuana stocks share a ton of the same dangers that accompany penny stocks. Numerous exchange on over-the-counter sheets for under $1 an offer, and they are helpless against misrepresentation. Besides, requirement and numerous government officials consider weed unlawful, and they need to stop the spread of this sprouting industry.

Still, a lot of theoretical financial specialists are longing for a hit. They accept what was as of late a bootleg market security has risen up out of the fog into an offering that may give some exceptional yields. Here are the business’ three key parts, and a top pick inside everyone.

Arena Pharmaceuticals, Incorporated, drives pharma and examination. The organization grows new medications to address unmet medicinal necessities. Most important is one of its more up to date manifestations, ADP371, which is proposed to oversee interminable agony while saving the client of Marijuana psychotropic impacts.

Among makers, Tweed Marijuana Incorporated emerges. It as of late converged with Bedrocan Cannabis Corporation to wind up Canada’s pioneer. Tweed joins Bedrocan’s exploration and clinical qualities with Tweed’s retail skill. It has delivered income – dissimilar to numerous pot stocks – and numerous examiners figure more to come.

In the consumer part, CannaVEST Corporation delivers and offers crude hemp oil and shop items, for example, body analgesics and healthy skin moisturizers. Its items contain hemp-based mixes made with cannabidiol, a non-psychoactive marijuana part that has been appeared to treat social uneasiness issue, sleep deprivation and epilepsy.

The legitimate cannabis organizations should fight through huge difficulties; be that as it may, right now the green business is blasting, giving speculators high trusts in new companies in the lawful weed space. Rather than battling against cannabis business people, numerous states, for example, Colorado and Washington are gaining by their trailblazers. By authorizing pot, governments give controlling direction to an answer that is both beneficial and safe
[custom-twitter-feeds hashtag=”#marijuanastocks”]

Read More

Headquartered in Henderson, Nevada, mCig Inc. (OTCQB:MCIG)

Headquartered in Henderson, Nevada, mCig Inc. (OTCQB:MCIG)

Headquartered in Henderson, Nevada, mCig Inc. (OTCQB:MCIG) continues to enhance its organization through servicing the lawful cannabis, hemp and CBD markets through its way of lifestyle brands.

MCIG has transitioned from a vaporizer maker to industry driving substantial scale, full service cannabis development organization with its Scalable Solutions division at present working in the quickly growing Nevada market.

The company’s share price currently trades around $0.029 per share with average daily volume of 225,070 shares. Its outstanding shares are standing around 326,755,392, while authorized shares are at 560,000,000.

It recently announced very strong results for fiscal year 2016. The company generated a revenue growth of almost 238% to $1,723,241, compared with the revenue of $509,957 in the same period of last year.

Its gross profit margin also enlarged 169% to $290,773 in fiscal 2016, compared with the gross margin of $108,051 in fiscal 2015

Mike Hawkins, Interim Chief Financial Officer, stated, “We are extremely pleased with the direction and performance of MCIG. We will be hosting our second quarterly shareholders update call on September 20, to discuss its operations and first quarter results of the new fiscal year.

Fiscal 2016 has been much better for shareholders of mCig Inc (OTCMKTS:MCIG) than 2015. There are a number of factors driving this optimism. Most importantly, investors look to have finally gotten over the hangover from the pot stock crash of 2014 and are looking to take advantage of the coming Green Rush 2.0, which looks to be starting this year.

Fiscal 2016 remained a strong years for shareholders of mCig compared with 2015. There are various components driving this positive thinking. Above all, speculators hope to have at last gotten over the after effect from the pot stock accident of 2014 and are hoping to exploit the coming Green Rush 2.0, which appears to begin this year.

Read More

Grow Condos, Inc. (OTCQB:GRWC)

Grow Condos, Inc. (OTCQB:GRWC)

Grow Condos, Inc. (OTCQB:GRWC ), is a fully reporting publicly traded company specialized in cannabis industry related “Condo” style real estate and turn-key grow facilities. The company is recently upgraded to its new tier level of OTCQB. Its outstanding shares are around 28,289,123, while authorized share are around 1,000,000,000.

Grow Condos has rapidly gotten to be a standout amongst the most energizing names on the OTC markets. In the beginning of this year, its share has tripled as speculators have gone looking for the following hot pot stock for their portfolios. Its stock is currently trading around $0.75 a share.

Speculators have immediately figured out how to stay away from a significant number of the old pot stocks that have pulverized their shareholders with weakening on the back of lethal financings. The answer is in discovering clean arrangements like GRWC.

We think 2016 will be an incredible year for the marijuana business. The reason being is that the pot business has a great deal of tailwinds heading into 2016. Around 14 states could legitimize weed for the current year, either at the tallying station or through state governing bodies.

GRWC is set superbly to exploit these patterns. Grow Condos is a land buyer, engineer and administrator of particular use mechanical properties giving “condominium” style turn-key develop offices to bolster the cannabis business.

The organization claims, rents, offers and oversees multi-occupant properties. It is centered on the pick-and-scoop way to deal with taking part in the detonating weed industry. Grow Condos right now possesses and deals with a 15,000 square foot distribution center in Eagle Point, Oregon and is building up a property in Eugene, Oregon. A month ago, GRWC declared a speculation concurrence with Tangiers Global LLC for up to $5 million dollar.

Read More

Growblox Sciences Inc (OTCMKTS:GBLX)

Growblox Sciences Inc (OTCMKTS:GBLX)

Growblox Sciences Inc (OTCMKTS:GBLX) is a biotechnology research and development company focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies that target a variety of medical conditions.

Growblox Sciences keeps on moving relentlessly higher as of late on quickening volume and recharged Interest from Investors since climbing off its $0.25 base. GBLX began exchanging as Growblox Sciences Inc in April of a year ago after the name change from Signature Exploration and Production Corp.

GB Sciences’ spearheading independent developing unit detaches and secures the plants growing inside while producing perfect developing situations to guarantee great, immaculateness, and consistency.

The company’s main product line include: TissueBLOX, GrowBLOX, CureBLOX and GB Sciences ApotheCAREians.

TissueBLOX – The tissue culture hatchery is customized to manage lighting, temperature, and dampness to encourage cell augmentation and the arrangement of fetuses and shoots from the sterile explants.

GrowBLOX™ – GB Sciences’ spearheading independent developing unit that secludes and ensures the plants becoming inside while creating perfect developing situations

CureBLOX™ – The CureBLOX™ module empowers us to dispense with the danger of mold development and guarantee that the concoction profile of our items is steady from harvest to reap.
GB Sciences ApotheCAREians – Highly prepared and affirmed ApotheCAREians work with patients to decide their restorative needs, distinguish remedial items, introduce GB Sciences’ application on their hand-held gadgets, and exhibit how to place orders.

Its stock price currently trades around $0.30 per share with an average volume of 97,575 share. Its market capitalization stands around $19 million, while the company has negative earnings per share of $0.14 in the latest earnings release. Its outstanding shares are around 57,448,614, while authorized shares are at 250,000,000. The company has taken several key initiatives to expand its revenue base and market share. It recently opened first marijuana dispensary in the month of July.

Read More

Creative Edge Nutrition Inc- FITX

Creative Edge Nutrition Inc (OTCMKTS:FITX)

Creative Edge Nutrition Is Moving in a Positive Direction

Creative Edge Nutrition Inc (OTCMKTS:FITX) keeps on moving relentlessly higher as of late since switching off $0.0025 lows prior this year. The stock keeps on getting a help from news on its backup Giddy Up Energy Products, Inc., and its arranged dispatch of its two starting caffeinated drink flavors, Peach Mango and Cherry Pear.

Like no other pot stock FITX was the best in catching the creative abilities and wallets of little top financial specialists. At its tallness the stock was practically similar to a clique with shareholders offering shirts that said “FITX-Long” or “I-Billieve” (as in president and CEO of FITX, Bahige “Charge” Chaaban).

Pot stocks (and FITX will move with the segment) might be in for another blast; DEA being advised by California judge to quit meddling with dispensaries, 6,000 peaceful medication guilty parties were just discharged Nov 1, New York opening restorative MJ dispensaries January, Australia lifting restriction on therapeutic MJ. Another huge one is Canada’s new Prime Minister Justin Trudeau who has been promising legitimization quickly in Canada.

FITX is the umbrella holding organization situated in Madison Heights, Michigan. The Company is going up by new CEO James Robinson who have a dream to dispatch an industry driving caffeinated drink line and to quicken income, accomplish benefit and shareholders’ esteem. Under the FITX umbrella, there are 2 essential business auxiliaries:

CEN-BIOTECH as beforehand depicted “This auxiliary is included underway and conveyance of therapeutic pot, and is situated in Lakeshore, Ontario, simply outside Windsor in Canada. FITX is one of the not very many genuine “MMJ” stocks which will really create the maryjane, rather than most other that are included with other subsidiary parts of the weed, for example, CBD extricates, CBD examine, edibles, smoking or developing gadgets, and so on.”

Update: Canada’s Legislation Could Enhance Creative Edge Nutrition Shares

Creative Edge Nutrition Inc (OTCMKTS:FITX) keeps on moving relentlessly higher as of late since turning around off $0.0025 lows prior this year. The stock keeps on getting a support from news on its auxiliary Giddy Up Energy Products, Inc., and its arranged dispatch of its two introductory caffeinated drink flavors, Peach Mango and Cherry Pear.

Like no other pot stock FITX was the best in catching the creative energies and wallets of little top financial specialists. At its stature the stock was practically similar to a religion with shareholders offering shirts that said “FITX-Long” or “I-Billieve” (as in president and CEO of FITX, Bahige “Charge” Chaaban).

CEN-BIOTECH as already portrayed “This auxiliary is included underway and appropriation of medicinal marijuana, and is situated in Lakeshore, Ontario, simply outside Windsor in Canada. FITX is one of the not very many genuine “MMJ” stocks which will really create the pot, rather than most other that are included with other subsidiary parts of the marijuana, for example, CBD extricates, CBD look into, edibles, smoking or developing gadgets, and so on.”

Canada’s legislature is concentrating a government team’s proposals on how it could authorize marijuana, following through on Prime Minister Justin Trudeau’s 2015 decision battle guarantee.

The proposition incorporate a base buy age of 18, elected oversight on creation, commonplace governments accused of retail dispersion and keeping up criminal offenses for unlawful generation and trafficking.

Read More

CGrowth Capital Inc (OTCMKTS:CGRA)

CGrowth Capital Inc (OTCMKTS:CGRA)

CGrowth Capital Inc (OTCMKTS:CGRA) is one penny stock that has everyone consideration running from $0.0008 lows prior this year to late highs well over the $0.02 mark. Its authorized Shares stands around 500,000,000, while outstanding share are at 391,597,994 The stock has likewise pulled in an expansive after that has changed CGRA into a volume pioneer.

CGRA began to pursue in April the execution of a LOI with Wildfire Cannabis Company, LLC to rent a part of their properties in Chewelah, Washington to develop pot. CGRA immediately picked up endorsements by both Stevens County and the condition of Washington most likely because of the way that they have 2 wells nearby that can pump 5000/gal a day.

At present they are dealing with the underlying 90,000 square feet of shelter space and are working towards multiplying its ability amid the year for a sum of six authorized occupants (there are as of now three inhabitants under contact). Under the Company’s turnkey lease terms, the rental potential is in abundance of $2,000,000 every year.

CGrowth Capital has generally charged itself as a holding organization for organizations and resources concentrated on all parts of mining, minerals, investigation, and business land.

The Company claims around 47 net sections of land of industrial area property and also more than 1000 sections of land of mineral rights and lease situated in Stevens County, Washington. As of late CGRA has started to deliberately influence resources for greatest quality inside the lawfully creating cannabis industry right now in progress in Washington State.

Read More



CV Sciences Is on Uptrend

CV Sciences Inc (OTCMKTS:CVSI) is a stock that has been driving in an uptrend helped along by late energy in the cannabis-related space as we rush into the real impetus one week from now on Tuesday. That is when almost 33% of the US populace will hit the voting stalls to set down judgment on the future legitimateness of pot crosswise over nine distinct states.

Be that as it may, CVSI kept running into close term reality this week when the organization came to advertise with its most recent financials. Long story short, the best possible move here was taken by the organization as far as speculator relations: concentrate on the pipeline and R&D activities on the grounds that the present numbers aren’t much to keep in touch with home about.

CVSI outlines itself as an existence science organization, concentrates on creating and commercializing novel therapeutics using engineered Cannabidiol (CBD).

CVSI works two particular business fragments: a medication improvement division concentrated on creating and commercializing novel therapeutics using engineered CBD; and, a buyer item division in assembling, advertising and offering plant-based CBD items to a scope of market segments, including nutraceutical, magnificence mind, forte sustenances, and vape.

Taking after the CanX Acquisition in December 2015, CV Sciences started its preclinical medication improvement program amid the second quarter of 2016. The Company’s medication advancement endeavors incorporate seeking after manufactured based Cannabidiol tranquilize applicants in zones that can possibly give noteworthy changes in remedial patient medicines with sizable addressable markets.

CVSI was once in the past known as CannaVEST Corp. furthermore, changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. has essential workplaces and offices in Las Vegas, Nevada and San Diego, California.

CVSI is driven by Michael J. Mona, JR. organizer of CV Sciences, Mr. Mona has more than 30 years of senior administration involvement in a scope of enterprises including land/development, mechanical cultivating, synthetic handling and customer items. Mr. Mona is a perceived industry pioneer in hemp cultivating operations and compound extraction and has built up a worldwide store network of hemp-inferred items.

Read More

Cannabis Science Inc (OTCMKTSCBIS)

Cannabis Science Inc (OTCMKTSCBIS)

Cannabis Science Could Make a Bid rebound

Cannabis Science Inc (OTCMKTS:CBIS) has been running up the outlines as a standout amongst the most drastically fruitful OTC entertainers available amid the second 50% of 2016. This activity is in direct expectation of the potential for an extended legitimate impression for weed related business in the US that could originate from voting in a few days, on November 8, when about 33% of the US populace partakes in nine state voting choices on the lawful status of cannabis.

CBIS is an organization that has been taking an interest in the development fervor through dynamic moves striking associations in land bargains for creation and advancement to permit the organization to scale up its volume to meet the bigger market. The diagram indicates 200% attached on to share valuing for the stock in the previous month. Advertise members might need to focus on this stock. CBIS stock has a past covered with sudden tears. Besides, the stock has enlisted expanded normal exchange volume as of late, with the previous month seeing barely short of 310% as time goes all things considered.

CBIS outlines itself as an organization that creates, delivers, and markets phyto cannabinoid-based pharmaceutical items basically in the United States. The organization is included in creating medications for a mental imbalance, circulatory strain, malignancy and growth symptoms, and in addition for different ailments containing for general wellbeing upkeep. It likewise creates CS-TATI-1 for recently determined and treatment-experienced patients to have medicate safe HIV strains, and those narrow minded of accessible treatments; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a restrictive cannabis-based treatment for neurological conditions.

Likewise, the organization offers an online video-based medicinal cannabis instruction framework, including courses, for example, therapeutic cannabis law, restorative pot, cooking, cultivation, and bud tending; and produces and disperses claim to fame steed and pet preparing and topical applications. It has a permit concurrence with Apothecary Genetics Investments LLC to create different brand details for California therapeutic cannabis advertise.

The organization likewise has joint effort with IGXBio, Inc. to create GenePro, a DNA-based immunotherapeutic medication. Cannabis Science, Inc. is situated in Colorado Springs, Colorado. Cannabis Science Inc is a backup of Weedmaps Media, Inc.

Read More

Cannabics Pharmaceuticals Inc (CNBX)

Cannabics Pharmaceuticals Inc (CNBX)

It’s time to Buy Cannabics Pharmaceuticals

Cannabics Pharmaceuticals Inc (CNBX) is a biotechnology pharmaceutical organization that is centered around advancement and authorizing of cannabinoid-based medicines and treatments. In that capacity, it creates and showcases different treatments and biotechnological devices went for giving help from infirmities that react to dynamic fixings sourced from the cannabis plant.

CNBX creates and showcases different treatments and biotechnological instruments went for giving help from infirmities that react to dynamic fixings sourced from the cannabis plant. These devices incorporate conveyance frameworks for cannabinoids, customized pharmaceutical treatments and strategies in light of cannabis started mixes, and bioinformatics apparatuses.

Its lead item is CANNABICS SR, which is an innovation for a long acting oil container that gives organization of cannabis. This is created exclusively from nourishment review materials and conveys impacts for more than 10 to 12 hours and the conveyance technique empowers an once every day dosing regimen of medicinal cannabis to patients.

The late decisions in the US additionally included voting on the legitimization of cannabis for medicinal or recreational use in specific states. The yes vote in states, for example, Florida will open a bigger market for this organization, which would mean bigger incomes down the line. Cannabics Pharmaceuticals Inc, be that as it may, hasn’t produced any incomes yet since it has been centered around generally investigate.

Just as of late, CNBX reported an examination achievement in finding a more powerful plan proportion of cannabis parts THC and CBD in fighting growth cells. Specifically, the organization shared that that outcomes from the most recent malignancy HTS look into obviously presume that, contingent on the THC/CBD proportion, particular Cannabis concentrates are straightforwardly contributive to diminishing U87MG glioblastoma cell reasonability.

This will empower the organization to make weed solutions gloating more prominent adequacy, potentially getting a charge out of a steady share of the therapeutic weed showcase. Beside that, the organization could likewise create additional incomes by adapting its disclosure to outsider designers of maryjane solutions.

Read More

CannaVest (CANV)

CannaVest (CANV),

CannaVest Looks Strong Aimed its Balance Sheet

CannaVest (CANV), exchanging simply off the 52-week lows, is looking increasingly like a magnificent microcap play for those hoping to enter the unstable yet high potential cannabis space. While microcap contributing involves a lifted level of hazard and a specific craving to act in a wander limit it can be unbelievably fulfilling on the off chance that you can distinguish wasteful aspects or unpredictable gathering offering inside an area.

“CannaVest Corp. creates, delivers, markets and offers raw materials and end buyer items containing the hemp plant extricate, Cannabidiol (“CBD”), to the nutraceutical, magnificence mind, pet care, claim to fame drink and practical nourishment areas.

To start with, you ought to comprehend that I’m arguing for a CANV thought working under the suspicion that cannabis will keep on being authorized broadly and that cannabis subsidiary items like those sold by CANV will keep on achieving more extensive social acknowledgment. While this has as of now happened to a more than least level degree, CANV had ~$10.2 million in item deals in entire year 2014, I anticipate that a proceeded with tailwind will be given at cannabis subordinates are coordinated into social standards.

All things considered, CANV surely isn’t a “pot stock” as it has been assembled in and sold off as – you don’t have $10 million or more entire year incomes being a pot stock. CANV has genuine operations, genuine supply concurrences with European providers, genuine appropriation limit, and clearly genuine financial specialists.
CANV as of late shut a $6.5 million financing with an institutional speculator that will be given in a progression of tranches. The financing will be utilized for working capital as CANV hopes to keep on scaling up its operations. This financing alongside liquidity as of now on the CANV monetary record ought to go far into accomplishing organization objectives.

That is the other thing about CANV that is profoundly surprising for a microcap. CANV’s monetary record as of Q1/15 reporting looks strong. The organization had, preceding the financing, $2.23 million in real money, $1.2 million in AR, $2.3 million in prepaid stock, and $10.7 million in stock. Of its aggregate ~$23.4 million in resources just generally $4.2 million was in Intangibles and Goodwill – such a light weighting is an irregularity in the microcap space. CANV likewise just as Accounts Payable of ~$500,000 and no obligation. Once more, that is an extraordinary place to begin.

Read More